{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-182838","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2022-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.331186+00:00","generated_at":"2026-06-24T23:00:56.742407+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cullinan Oncology closes $275M sale of Cullinan Pearl to Taiho; co-development deal for CLN-081","bullets":["Upfront cash payment of $275M from Taiho; potential $130M in regulatory milestones for CLN-081/TAS6417.","Taiho obtains exclusive global rights outside U.S.; companies co-develop and co-commercialize CLN-081 in U.S.","U.S. profits and development costs split 50/50 between Cullinan and Taiho; Cullinan retains co-commercialization option.","Deal includes sale of Cullinan Pearl Corp., which holds ex-Japan rights to CLN-081/TAS6417."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-182838","json":"https://secwatch.observer/filing/0001193125-22-182838.json","markdown":"https://secwatch.observer/filing/0001193125-22-182838.md","text":"https://secwatch.observer/filing/0001193125-22-182838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522182838/0001193125-22-182838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522182838/d278047d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T23:00:56.742407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}